Trabecular carcinoma of the skin

Toker, C.

doi:10.1001/archderm.105.1.107

Cited by 399 publications

(292 citation statements)

References 0 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…Neuroendocrine tumors can originate from neuroendocrine cells that reside within the basal layer of the epidermis (Merkel cell carcinoma) [7]. Since its first description by Toker [8] in 1972, about 1,000 cases have been reported. As these tumors frequently cannot be clearly differentiated from other neuroendocrine tumors by histology and as expression of cytokeratin 20 is found in Merkel cell carcinomas, the tumor manifestation in our patient could theoretically also represent a lymph node metastasis from a Merkel cell carcinoma [9].…”

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Carcinoma of Inguinal Lymph Node

Biering

Bauditz²,

Brenner³

et al. 2005

Horm Res Paediatr

View full text Add to dashboard Cite

Ninety-seven percent of neuroendocrine carcinomas are located in the gastrointestinal tract or in the bronchopulmonary tree. Inguinal lymph nodes as the primary tumor site for neuroendocrine carcinoma represent a very unusual location, and have only been described in 2 patient series in the literature. A 64-year-old, previously healthy, Caucasian female presented with a 2-month history of an enlarged inguinal lymph node on the right side. The removed lymph node showed histological and immunohistochemical characteristics of neuroendocrine differentiation (positive for synaptophysin, cytokeratin 20, neuron-specific enolase and chromogranin A). Although extensive investigations including repeated CT and NMR scans, classical endoscopy, wireless capsule endoscopy of the small intestine, octreotide- and MIBG scintigraphy were performed, no other primary tumor was found. Furthermore, there was no evidence of Merkel cell carcinoma on dermatological examinations. A possible explanation for the presence of neuroendocrine carcinomas within the lymph nodes is malignant transformation of preexisting intranodal epithelial nests, which have previously been described in lymph nodes located close to the salivary glands, thyroid gland, breast tissue and pancreas. Since the surgical removal of the affected lymph node, the patient has now been disease-free for 42 months. We therefore consider our case to represent a primary undifferentiated neuroendocrine carcinoma in an inguinal lymph node.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Carcinoma of Inguinal Lymph Node

Biering

Bauditz²,

Brenner³

et al. 2005

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine tumor of the skin, first described by Toker in 1972 [1]. Clinically, it usually appears as a firm, dome-shaped, red to deep purple nodule, mostly located on the head and neck of elderly people [2, 3].…”

Section: Introductionmentioning

confidence: 99%

Differentiation between Merkel Cell Carcinoma and Malignant Melanoma: An Immunohistochemical Study

et al. 2000

View full text Add to dashboard Cite

Background: Although Merkel cell carcinoma (MCC) exhibits specific clinical and histologic features, differentiation from other cutaneous neoplasms, such as lymphoma, metastatic oat cell carcinoma and malignant melanoma (MM), may sometimes be difficult. Objective: The aim of our study was to immunohistochemically differentiate MCC from MM. Methods: Paraffin sections from 6 cases of primary MCC and 6 cases of primary MM were investigated. For immunostaining, the APAAP method was used. Results: Neuron-specific enolase was positive in all cases of MCC, as well as in 2 cases of MM. Marked positivity for cytokeratins 18, 20 and chromogranin A was observed in the MCC group, whereas a complete absence of expression of these three markers was noted in the MM group. Immunostaining with HMB45 and NKI/C3 was positive in all cases of MM and negative in all cases of MCC. S-100 protein was positive in all but 1 case of MM. In contrast, only 1 case of MCC reacted with S-100 protein. Conclusion: Our results underline the role of immunohistochemistry in the diagnosis and differential diagnosis of MCC. In particular, the combination of neuron-specific enolase, cytokeratins 18, 20 and chromogranin A positivity for MCC and HMB45, NKI/C3 and S-100 protein positivity for MM is of great value in the distinction between these two cutaneous neoplasms.

show abstract

“…It was originally described by Toker [1]in 1972 as trabecular carcinoma, arising from immature cells from the dermis or subcutis, capable of giving rise to primitive sudoriferous cells. Today, we know that it belongs to the family of undifferentiated NET, like small cell lung cancers (SCLC).…”

Section: Merkel Cell Carcinomamentioning

confidence: 99%

Successful Targeted Radiotherapy with <sup>90</sup>Y-DOTATOC in a Patient with Merkel Cell Carcinoma

Meier¹,

Waldherr

Herrmann³

et al. 2004

Oncology

View full text Add to dashboard Cite

Merkel cell carcinomas (MCC) belong to the family of neuroendocrine tumors. In addition to other markers, they express somatostatin receptors. They are uncommon, highly malignant skin tumors with an aggressive clinical course. They develop in sun-exposed areas of the skin, mostly in elderly patients. In addition to frequent locoregional recurrences, there is a high incidence of distant metastases. Treatment is stage dependent and consists of operation and chemo- and/or radiotherapy, respectively. The advanced age of patients often impedes adequate therapy. ⁹⁰Y-DOTATOC is a novel radiolabeled somatostatin analogue containing the active octapeptide of somatostatin. It is very well tolerated and offers the option of treating somatostatin receptor-positive tumors by targeted radiotherapy. We report the case of an 83-year-old woman with recurrent MCC of the left cheek. The primary tumor and several relapses were treated with surgery and locoregional radiotherapy. After the 3rd relapse, she was treated 4 times with ⁹⁰Y-DOTATOC and two complete remissions were achieved. The fourth administration after the 2nd relapse was ineffective and conventional chemotherapy was started. There were no side effects of the ⁹⁰Y-DOTATOC. We conclude that due to its good tolerability, ⁹⁰Y-DOTATOC therapy should be evaluated further as a new therapy for somatostatin receptor-positive MCC.

show abstract

Trabecular carcinoma of the skin

Cited by 399 publications

References 0 publications

Primary Neuroendocrine Carcinoma of Inguinal Lymph Node

Primary Neuroendocrine Carcinoma of Inguinal Lymph Node

Differentiation between Merkel Cell Carcinoma and Malignant Melanoma: An Immunohistochemical Study

Successful Targeted Radiotherapy with <sup>90</sup>Y-DOTATOC in a Patient with Merkel Cell Carcinoma

Contact Info

Product

Resources

About